ArticleBMC immunology2025
The effectiveness of unfractionated heparin vs. low molecular weight (Enoxaparin) in Acute Respiratory Distress Syndrom (ARDS) and metabolic dysfunction: an old drug for new indication!
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Respiratory Distress Syndrome is a lung disorder defined by the acute onset of hypoxemia, the commonest being abdominal sepsis.Many biomarkers have been studied for diagnostic prognostication and ARDS pharmacotherapy. The current study aim to assess the protective effects of UFH versus Enoxaparin in sepsis-induced ARDS and related metabolic sequelae.
methodsSepsis was initiated through cecal ligation and puncture (CLP). Wistar rats were divided to: sham, CLP, CLP + unfractionated Heparin, and CLP + Enoxaparin and CLP + distilled water groups. Levels of serum Lipoxin A4 (LXA4), lipoprotein lipase (LPL), leukotriene E4 (LTE4), leukotriene B4 (LTB4), interleukin-8 (IL-8), were quantified. Furthermore, mRNA expression of receptors for advanced glycation end products (RAGE) and angiopoietin-2 (ANG-2) were assessed. Histopathological study was conducted to assess any lung injuries.
resultsSeptic rats demonstrated higher levels of leukotriene E4, leukotriene B4, and interleukin-8, while treatment with unfractionated Heparin attenuated these levels but enoxaparin effectiveness on LTB-4 and IL-8 was not as significant as heparin while its was equally effective on LTE-4. Moreover, mRNA levels of RAGE and ANG-2 were enhanced in CLP rats. These elevations were mitigated by treatment with unfractionated Heparin and reduced by enoxaparin to a lesser extent. Treatment with unfractionated Heparin increased the lipoxin A4 and lipoprotein lipase levels but enoxaparin had no effect on the LPL level. Lung protective effect of unfractionated Heparin was further confirmed by histopathological observations of lung tissue samples.
conclusionOur study demonstrates that UFH can modulate ARDS and metabolic dysfunction in hyperinflammatory conditions like sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.